Sun Pharma to acquire Concert Pharmaceuticals to bolster dermatology franchise
India-based Sun Pharmaceutical Industries (Sun Pharma) will acquire US-based Concert Pharmaceuticals for equity consideration of $576 million to strengthen its global dermatology franchise. Concert Pharmaceuticals is developing deuruxolitinib, a novel, deuterated, oral Janus kinases JAK1/2 inhibitor for the treatment of Alopecia Areata, an autoimmune dermatological disease resulting in partial or complete loss of hair on […]